Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo.

  • Keld Danø
  • Published 1972 in Cancer chemotherapy reports


Resistance to adriamycin was developed in an originally adriamycin-sensitive wild strain of Ehrlich ascites tumor (EHR 2) in vivo by treatment with the drug during 25 weekly passages of the tumor. The growth of the resistant line was slower than that of the wild tumor. The resistance was stable for more than 25 weeks both when adriamycin treatment was… (More)